Clinical trials: Disorder of Vein
Telangiectasis, Spider Veins
Treatment of Lower Extremity Spider Veins With Excel V
The purpose of this study is to evaluate the safety and effectiveness of a new laser for the removal of unsightly spider veins on the legs.
- Trial name
- NCT01362192
- Testing
- 532 nm KTP Excel V Laser, manufactured by Cutera, Inc.
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Cutera Inc.
Chronic Venous Disease
Clinical Trial to Assess the Efficacy of µSmin® Plus
This study evaluates treatment with the dietary supplement µSmin® Plus in a group of patients suffering from chronic venous insufficiency in comparison with a similarly-sized group of patients receiving placebo evaluated by…
- Trial name
- NCT04101201
- Testing
- µSmin® Plus
- Where
- Romania
- Volunteers
- 73 people
- Sponsor
- Giellepi S.p.A
Venous Thrombosis
Vasculaire Compression System Increases Flow Velocity in the Femoral Vein
The objective of this clinical study was to demonstrate the performance of the Vasculaire Compression System to increase femoral venous peak velocity (PFV) in healthy subjects.
- Trial name
- NCT01240330
- Testing
- Pneumatic Compression therapy
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Venous Health Systems, Inc.
Venous Thromboembolism
Rivaroxaban (10mg) Given Once Daily in Patients Undergoing Total Hip Replacement Compared to Enoxaparin
The purpose of this study is to assess if 10 mg BAY 59-7939, taken once daily as a tablet, is safe and prevent blood clot which may form after total hip replacement operation.
- Trial name
- NCT00329628
- Testing
- Rivaroxaban (BAY59-7939), Enoxaparin
- Where
- 215 sites in United States, Argentina and 26 more
- Volunteers
- 4,541 people
- Sponsor
- Bayer
Embolism, Atrial Fibrillation and Venous Thrombosis
Bioequivalence Study of Rivaroxaban in Japanese Healthy Adult Male Subjects
The objectives of this study are to establish the bioequivalence between rivaroxaban tablet 10mg and rivaroxaban granule formulation 10mg, and to assess the safety and tolerability of rivaroxaban 10mg in healthy adult male…
- Trial name
- NCT02537405
- Testing
- Rivaroxaban (BAY 59-7939), Rivaroxaban (Xarelto, BAY 59-7939)
- Where
- Japan
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Bayer
Circulatory Disease
Phase II Clinical Study of H001 Capsule in the Prevention of Venous Thromboembolism After Total Knee Arthroplasty
This study is a multicenter, randomized, open-label, positive-controlled Phase II clinical study to evaluate the efficacy and safety of H001 capsules in the prevention of venous thromboembolism (VTE) in subjects undergoing Total…
- Trial name
- NCT06963320
- Testing
- H001 Capsule 200mg-qd, Enoxaparin Sodium Injection, H001 Capsule 300mg-qd
- Where
- China
- Volunteers
- 320 people
- Sponsor
- Livzon Pharmaceutical Group Inc.
Thrombosis, Venous Thrombosis
Safety and Efficacy Study of Alfimeprase in Subjects With Occluded Catheters
To evaluate the safety profile of alfimeprase as assessed by monitoring of adverse events, serious adverse events and major bleeding events for up to 120 minutes following the instillation of study drug to an occluded central…
- Conditions
- Thrombosis, Venous Thrombosis, Catheter Occlusion
- Trial name
- NCT00322270
- Testing
- Alfimeprase
- Where
- 18 sites in United States
- Sponsor
- ARCA Biopharma, Inc.
Chronic Venous Leg Ulcers
Evaluation of CureXcell® in Treating Chronic Venous Leg Ulcers
The primary objective is to evaluate the clinical benefit of CureXcell® as adjunct to Standard of Care in the treatment of Chronic Venous Leg Ulcers.
- Trial name
- NCT02130310
- Testing
- CureXcell®
- Where
- 28 sites in United States
- Volunteers
- 252 people
- Sponsor
- Macrocure Ltd.
Deep-Vein Thrombosis
Oral Direct Factor Xa-inhibitor Apixaban in Patients With Acute Symptomatic Deep-vein Thrombosis-The Botticelli DVT Study
The purpose of this clinical research study is to assess efficacy and safety of 3 doses of apixaban 5 mg twice a day, 10 mg twice a day and 20 mg once daily versus conventional treatment with low molecular weight heparin or…
- Trial name
- NCT00252005
- Testing
- Apixaban
- Where
- 72 sites in United States, Australia and 9 more
- Volunteers
- 520 people
- Sponsor
- Bristol-Myers Squibb
End Stage Renal Disease
A Multi-Centered, Two-Arm, Randomized Study Comparing the Effects of AAT-023 (Zuragen) Solution, and Heparin on the Incidence of Catheter Related Blood Stream Infections in Tunneled Chronic Central Venous Catheters for Dialysis
The purpose of this study is to determine if AAT-023 (Zuragen) solution is superior to Heparin in preventing Catheter Related Blood Stream Infections for End Stage Renal Disease patients.
- Trial name
- NCT00628680
- Testing
- AAT-023 solution (Zuragen), Heparin
- Where
- 22 sites in United States
- Volunteers
- 415 people
- Sponsor
- Ash Access Technology
Validation of Oximeter System
Correlation of Venous Oxygen Saturation Measurements by Non-invasive Mespere Venous Oximeter and Central Venous Catheter
The purpose of this study is to establish the accuracy of the non-invasive Mespere Oximeter that estimates venous oxygen saturation.
- Trial name
- NCT01908790
- Testing
- Mespere Venous Oximeter, Avoximeter 4000
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Mespere Lifesciences Inc.
Coronary Artery Disease
Angioshield First-In-Human Study to Demonstrate the Preliminary Safety and Efficacy
The purpose of this study is to determine whether or not the Angioshield device can be safely applied to support saphenous vein grafts used in standard coronary bypass surgery.
- Trial name
- NCT02072239
- Testing
- Angioshield
- Where
- Poland
- Volunteers
- 13 people
- Sponsor
- Neograft Technologies, Incorporated
Liver Fibrosis Due to NASH
Simtuzumab (SIM, GS-6624) in the Treatment of Cirrhosis Due to NASH
The primary objective of this study is to evaluate the safety and efficacy of SIM (formerly referred to as GS-6624) in adults with compensated cirrhosis due to Non-Alcoholic Steatohepatitis (NASH).
- Trial name
- NASH (NCT01672879)
- Testing
- SIM
- Where
- 59 sites in United States, Canada and 6 more
- Volunteers
- 259 people
- Sponsor
- Gilead Sciences
Macular Edema, Macular Degeneration
Evaluation of the Retinal Health Monitoring System Thickness Module
Evaluate the ability and accuracy of the Retinal Health Monitoring System - Retinal Thickness Module (RHMS - RTM).
- Trial name
- NCT04499703
- Testing
- RHMS-RTM, SD-OCT
- Where
- Switzerland
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Kubota Vision Inc.
Central Venous Pressure
Correlation of Physical Exam Versus Non-invasive Assessment Versus Invasive Assessment of Central Venous Pressure
The purpose of this study is to establish the accuracy of a non-invasive device that uses near infrared spectroscopy (NIRS) to estimate central venous pressure (CVP) comparing it to physical exam and invasive hemodynamic…
- Trial name
- NCT01574690
- Testing
- Mespere Venus System, Right heart catheterization (RHC), Physical examination of jugular vein
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Mespere Lifesciences Inc.
Wounds, Wound of Skin
A Clinical Investigation to Follow the Progress of Exuding Chronic Wounds Using Mepilex® Up as the Primary Dressing.
The goal of this clinical trial is to follow the progress of wounds in those with venous leg ulcers and diabetic foot ulcers while using an absorbent dressing called Mepilex Up.
- Conditions
- Wounds, Wound of Skin, Wound Leg, Wound; Foot
- Trial name
- NCT05588583
- Testing
- Mepilex Up
- Where
- 4 sites in United States
- Volunteers
- 68 people
- Sponsor
- Molnlycke Health Care AB
Leg Ulcer
Use of dHACM in the Treatment of Venous Leg Ulcers
The overall objective of this study is to evaluate the effectiveness of dehydrated human amnion/ chorion membrane (dHACM) in reducing time to complete wound closure in patients with venous leg ulcers (VLUs).
- Trial name
- NCT02011503
- Testing
- Multi-layer compression therapy, Application of dHACM
- Where
- 15 sites in United States
- Volunteers
- 128 people
- Sponsor
- MiMedx Group, Inc.
Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation
Automated Assessment of PVI Using a Novel EP Recording System
A prospective, multi-center study with the CathVision Cube® system and the PVI Analyzer software in radiofrequency (RF), cryo-balloon (CB), and Pulse Field Ablation (PFA) procedures.
- Trial name
- PVISION (NCT05043883)
- Testing
- CathVision Cube® system
- Where
- 4 sites in Belgium, France
- Volunteers
- 101 people
- Sponsor
- CathVision ApS
Multiple Sclerosis, Relapsing-Remitting
A Study of Allogeneic Human UC-MSC and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS
STUDY OBJECTIVES: Primary Objective: Assessment of treatment safety based on incidence of any treatment emergent/treatment associated adverse events prior to discharge and at 1, 3, 6 and 12 months post treatment.
- Trial name
- NCT02587715
- Testing
- Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells, Liberation therapy
- Where
- Trinidad and Tobago
- Volunteers
- 69 people
- Sponsor
- Novo Cellular Medicine Institute LLP
Thromboembolism
Secondary Prevention of Venous Thrombo Embolism (VTE).
The general aim of this study is to determine the comparative safety and efficacy of dabigatran etexilate administered orally and warfarin (International Normalized Ratio (INR) of 2.0-3.0) for the long-term treatment and…
- Trial name
- RE-MEDY (NCT00329238)
- Testing
- Dabigatran, Warfarin
- Where
- 275 sites in United States, Argentina and 31 more
- Volunteers
- 2,867 people
- Sponsor
- Boehringer Ingelheim